Lilly Oncology on Canvas Invites Entries

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

Eli Lilly and Company and the National Coalition for Cancer Survivorship have issued a call for entries for the 2006 Lilly Oncology on Canvas: Expressions of a Cancer Journey International Art Competition and Exhibition.

INDIANAPOLIS—Eli Lilly and Company and the National Coalition for Cancer Survivorship have issued a call for entries for the 2006 Lilly Oncology on Canvas: Expressions of a Cancer Journey International Art Competition and Exhibition. The competition invites people diagnosed with any type of cancer, their families and friends, cancer advocates, and health care providers, as well as artists and art students, to express, through art and narrative, their own cancer journeys. Art entries will be accepted through July 30, 2006, in the following media: oil, watercolor, acrylic, pastel, photography, and other one-dimensional art. Winners of the 2004 competition can be viewed at www.lilly.com. For additional contest details and to obtain a registration form, please call 1-800-734-4131 or contact Anita Chernewski, art director, at achernewski@cprworldwideusa.com.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content